Heterogeneity of myocardial iron distribution in response to chelation therapy in patients with transfusion-dependent anemias

被引:0
|
作者
Kate Hanneman
Vikram M. Raju
Hadas Moshonov
Richard Ward
Bernd J. Wintersperger
Andrew M. Crean
Heather Ross
Elsie T. Nguyen
机构
[1] University of Toronto,Division of Cardiothoracic Imaging, Department of Medical Imaging, University Health Network, Toronto General Hospital
[2] University of Toronto,Division of Hematology, Department of Medicine, Toronto General Hospital
[3] University of Toronto,Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network
关键词
Magnetic resonance imaging; T2* imaging; Thalassemia; Iron overload; Cardiomyopathy;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this study is to examine the effect of different iron chelation regimens on the distribution of myocardial iron in patients with transfusion-dependent anemias. Institutional review board approval was obtained. Patients treated with iron chelation therapy who had undergone baseline and 1-year follow-up cardiac T2* MR studies in a four-year period were identified retrospectively. One hundred and eight patients (44 % male, mean age 31.6 ± 9.7 years) were included. The interventricular septum on three short-axis slices (basal, mid and apical) was divided into anterior and inferior regions of interest for T2* analysis. Cardiac iron concentration (CIC) was calculated from T2* values. Statistical analysis included analysis of variance and paired t-test, using Bonferroni adjustment in all pairwise comparisons. At baseline, T2* measurements varied significantly across all six regions (p < 0.001): lowest in the mid anteroseptum (mean 22.3 ± 10.1 ms) and highest in the apical inferoseptum (mean 26.2 ± 12.8 ms). At follow-up, T2* and CIC values improved significantly in all segments [mean change of 3.78 ms (95 % CI (2.93, 4.62), p < 0.001) and 0.23 mg/g (95 % CI (0.16, 0.29), p < 0.001), respectively]. Change in T2* values varied significantly between segments (p < 0.001) with greatest improvement in the apical inferoseptum [4.26 ms, 95 % CI (2.42, 6.11)] and least improvement in the basal anteroseptum [2.95 ms, 95 % CI (1.37, 4.54)]. The largest improvement in T2* values was noted in patients treated with deferiprone [4.96 ms, 95 % CI (2.34, 7.58)]. There was a statistically significant difference in improvement in CIC values between chelation regimens (p = 0.016). This is the first study to report heterogeneity in response to iron chelating drugs with variable segmental changes in T2* values.
引用
收藏
页码:1517 / 1526
页数:9
相关论文
共 50 条
  • [41] Deferasirox Efficacy and Safety for the Treatment of Transfusion-Dependent Iron Overload in Patients with a Range of Rare Anemias.
    Porter, John B.
    Lin, Kai-Hsin
    Habr, Dany
    Domokos, Gabor
    Hmissi, Abdel
    Thein, Swee Lay
    BLOOD, 2008, 112 (11) : 506 - 506
  • [42] Iron Chelation in Patients with Transfusion Dependent Thalassemia: An Insight on Response to Deferasirox
    Shaikh, Muhammad Shariq
    Adil, Salman Naseem
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2015, 25 (07): : 553 - 554
  • [43] Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
    Origa, Raffaella
    Cinus, Monia
    Pilia, Maria Paola
    Gianesin, Barbara
    Zappu, Antonietta
    Orecchia, Valeria
    Clemente, Maria Grazia
    Pitturru, Carla
    Denotti, Anna Rita
    Corongiu, Francesco
    Piras, Simona
    Barella, Susanna
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (07)
  • [44] Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
    Michael D. Diamantidis
    Nikolaos Neokleous
    Aleka Agapidou
    Evaggelia Vetsiou
    Achilles Manafas
    Paraskevi Fotiou
    Efthymia Vlachaki
    International Journal of Hematology, 2016, 103 : 537 - 544
  • [45] ECHOCARDIOGRAPHIC ABNORMALITIES IN PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA AND SECONDARY MYOCARDIAL IRON DEPOSITION
    HENRY, WL
    NIENHUIS, AW
    WIENER, M
    MILLER, DR
    CANALE, VC
    PIOMELLI, S
    AMERICAN JOURNAL OF MEDICINE, 1978, 64 (04): : 547 - 555
  • [46] Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
    Diamantidis, Michael D.
    Neokleous, Nikolaos
    Agapidou, Aleka
    Vetsiou, Evaggelia
    Manafas, Achilles
    Fotiou, Paraskevi
    Vlachaki, Efthymia
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (05) : 537 - 544
  • [47] Current recommendations for chelation for transfusion-dependent thalassemia
    Kwiatkowski, Janet L.
    COOLEY'S ANEMIA, 2016, 1368 : 107 - 114
  • [48] Deferasirox: optimal chelation in transfusion-dependent anaemia
    Perrotta, S.
    Casale, M.
    PEDIATRIC REPORTS, 2012, 4 : 29 - 33
  • [49] Iron Chelation Therapy in Transfusion Dependent Patients with Thalassemia and Minimal Liver Iron Load
    Kattamis, Antonios
    Stokidis, Konstantinos
    Petropoulou, Tbeoni
    Kyriacopoulou, Dimitra
    Delaporta, Polyxeni
    Papassptiriou, Ioannis
    Ladis, Vassilis
    BLOOD, 2010, 116 (21) : 1733 - 1733
  • [50] Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
    Delforge, Michel
    Selleslag, Dominik
    Beguin, Yves
    Triffet, Agnes
    Mineur, Philippe
    Theunissen, Koen
    Graux, Carlos
    Trullemans, Fabienne
    Boulet, Dominique
    Van Eygen, Koen
    Noens, Lucien
    Van Steenweghen, Steven
    Lemmens, Jan
    Pierre, Pascal
    D'hondt, Randal
    Ferrant, Augustin
    Deeren, Dries
    Van De Velde, Ann
    Wynendaele, Wim
    Andre, Marc
    De Bock, Robrecht
    Efira, Andre
    Breems, Dimitri
    Deweweire, Anne
    Geldhof, Kurt
    Pluymers, Wim
    Harrington, Amanda
    MacDonald, Karen
    Abraham, Ivo
    Ravoet, Christophe
    LEUKEMIA RESEARCH, 2014, 38 (05) : 557 - 563